These stem cell lines may not be representatve of what is happening in a large proportion of prostate cancers. Certainly, genetic profiling of tumors is just in its infancy and will become an integral part of choosing therapies and predicting survival.
Unfortunatly for provenge we dont understand the moa and the target well. Even If it works still many patients still die. It would be useful to develop an assay that would predict response. That may be genetic or something as simple as pap concentration in tumors or even an immune assay. Drug companies dont pursue this sort of research enough. I wonder whether thats because weeding out those who might benefit from a therapy beforehand interferes with the bottom line.
News 
Market Data 
Discover 
